Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsyn (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), L. Slogodskay (Moscow, Russian Federation). Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients. 2990

Member's Comments

No comment yet.

Related content which might interest you: Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The tuberculosis in patients with HIV and AIDS Source: Eur Respir J 2007; 30: Suppl. 51, 656s Year: 2007 Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Characteristics of tuberculosis patients co-infected with COVID-19 Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021 Treatment outcomes of MDR-TB and HIV co-infection in Europe Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016 Year: 2017 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 The incidence of MDR-TB in new and retreatment cases of HIV and pulmonary tuberculosis co-infection Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013 Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Hospitalized tuberculosis: HIV versus non-HIV patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Evaluation of the multidrug resistant TB in children with HIV infection Source: Eur Respir J 2004; 24: Suppl. 48, 439s Year: 2004 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013